Friese-Hamim M - Search Results

1

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.

Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. Falchook GS, et al. Clin Cancer Res. 2020 Mar 15;26(6):1237-1246. doi: 10.1158/1078-0432.CCR-19-2860. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822497 Free article. Clinical Trial.

2

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.

Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A. Bladt F, et al. Clin Cancer Res. 2013 Jun 1;19(11):2941-51. doi: 10.1158/1078-0432.CCR-12-3247. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553846

3

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.

Bladt F, Friese-Hamim M, Ihling C, Wilm C, Blaukat A. Bladt F, et al. Cancers (Basel). 2014 Aug 19;6(3):1736-52. doi: 10.3390/cancers6031736. Cancers (Basel). 2014. PMID: 25256830 Free PMC article.

4

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.

Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A. Dorsch D, et al. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1597-602. doi: 10.1016/j.bmcl.2015.02.002. Epub 2015 Feb 16. Bioorg Med Chem Lett. 2015. PMID: 25736998

5

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

Friese-Hamim M, Bladt F, Locatelli G, Stammberger U, Blaukat A. Friese-Hamim M, et al. Am J Cancer Res. 2017 Apr 1;7(4):962-972. eCollection 2017. Am J Cancer Res. 2017. PMID: 28469968 Free PMC article.

6

Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.

Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S. Xiong W, et al. Among authors: friese hamim m. CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):428-440. doi: 10.1002/psp4.12602. Epub 2021 May 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33818908 Free PMC article.

7

Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.

Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, Zhang H, Crandall T, Lin J, Ma J, Bachner D, Schmidt J, Schaefer M, Stroh C. Friese-Hamim M, et al. Lung Cancer. 2022 Jan;163:77-86. doi: 10.1016/j.lungcan.2021.11.020. Epub 2021 Dec 11. Lung Cancer. 2022. PMID: 34942492 Free article.

8

Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma.

Lignet F, Esdar C, Walter-Bausch G, Friese-Hamim M, Stinchi S, Drouin E, El Bawab S, Becker AD, Gimmi C, Sanderson MP, Rohdich F. Lignet F, et al. Among authors: friese hamim m. J Pharmacol Exp Ther. 2023 Jan;384(1):163-172. doi: 10.1124/jpet.122.001355. Epub 2022 Oct 23. J Pharmacol Exp Ther. 2023. PMID: 36273822

9

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.

Albers J, Friese-Hamim M, Clark A, Schadt O, Walter-Bausch G, Stroh C, Johne A, Karachaliou N, Blaukat A. Albers J, et al. Among authors: friese hamim m. Mol Cancer Ther. 2023 Jul 5;22(7):833-843. doi: 10.1158/1535-7163.MCT-22-0537. Mol Cancer Ther. 2023. PMID: 36999986 Free PMC article. Review.

10

Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2.

Lignet F, Friese-Hamim M, Jaehrling F, El Bawab S, Rohdich F. Lignet F, et al. Among authors: friese hamim m. Pharm Res. 2023 Dec;40(12):3011-3023. doi: 10.1007/s11095-023-03611-z. Epub 2023 Oct 5. Pharm Res. 2023. PMID: 37798538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters